65 results about "Guanine nucleoside" patented technology

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The invention relates to chiral supramolecular nucleoside hydrogel based on a boron ester bonds as well as a preparation method and application of the chiral supramolecular nucleoside hydrogel, and particularly provides supramolecular hydrogel which is obtained by mixing guanine nucleoside and borate as raw materials in a solvent, wherein the guanine nucleoside is D-guanine nucleoside and/or L-guanine nucleoside. The supramolecular hydrogel has excellent stability, injectability and self-repairability, also has good biocompatibility, does not show obvious acute toxicity in animal bodies, can be degraded in vivo, and can be used as an extracellular matrix for 3D culture of cells. The supramolecular hydrogel provided by the invention has a very good application prospect in the field of tissue engineering as a scaffold material.

The invention provides a comprehensive recycling production process of guanosine. The bacterial suspension collected from the process in which guanosine is extracted and refined from guanosine fermented liquid is dried as feed additive or made into feed protein; the primary mother liquid acquired from the first four times during micro-filtrate membrane filtration, crude crystallization and pressure filtration and separation is sent into a reverse osmosis membrane for condensation and then mixed with the guanosine fermented liquid for internal recycling; the primary mother liquid acquired from the fifth time undergoes evaporation concentration, crystallization, drying and granulation to produce ammonium sulfate and other bio-compound fertilizers; the secondary mother liquid acquired from ultrafiltration membrane treatment is reused as micro-filtration membrane dialysis water; the third mother liquid acquired from extract crystallization and pressure filtration and separation is respectively reused as anti-crystallinic water of anti-crystallinic jar and dialysis water of micro-filtration membrane and ultrafiltration membrane. The invention overcomes the defects of the traditional process such as incomprehensive utilization, resources waste and environmental pollution; the comprehensive cycling process is reasonable and feasible and conforms to the green environmental protection concept, thus cleaning the environment, promoting the ecological balance, reducing the production cost and strengthening the social and economic benefits.

The invention provides self-repairing supermolecule hydrogel as well as a preparation method and use thereof. Particularly, the supermolecule hydrogel is prepared by the steps of dissolving L-type guanosine into a potassium chloride water solution, heating until boiling, and cooling at the room temperature after L-type guanosine is completely dissolved, so as to obtain the supermolecule hydrogel.Experimental results prove that the supermolecule hydrogel formed through the self-assembling of L-form guanosine has the advantages that the defects of D-type guanosine hydrogel are overcome, and thesupermolecule hydrogel presents very good self-repairing capacity and biocompatibility and has very good application prospects in the field of biological medicine.

The invention discloses a guanosine production method, which consists of four major technical processes including fluid strain cultivation in a shaking bottle, production of glucose solution, production of guanosine fermented fluid and extraction and refinement of guanosine, adopts a preserved strain TA208-IMPD with genetic stability, prepares the glucose solution by steeping, pulping, liquefying, filter pressing and saccharifying cracked grains, adopts new techniques including flow feeding of the glucose solution in a fermentation process, and produces qualified guanosine through microfiltration membrane sterilization, crude guanosine crystallization, ultrafiltration membrane decoloring and impurity removing, separating and parching of the guanosine fermented fluid. The guanosine production method overcomes the disadvantages of traditional new techniques that have behindhand culture techniques, lower guanosine yield of the strain, long fermentation period, lower transformation ratio and lower synthesized extraction yield, and the like, achieves high synchronized production efficiency and guanosine production level of the strain, stable glucose solution product and high guanosine fermented production level, and can reach the guanosine product purity of over 99 percent and the yield of over 80 percent.

The invention discloses a preparation method of acyclovir, and belongs to the field of organic compound synthesis. According to the method, guanosine is taken as a starting raw material and is subjected to reactions of acylation, condensation and hydrolysis to prepare the acyclovir. Compared with the prior art, the synthesis method has stable and abundant raw material sources, market fluctuation influences are small, reaction conditions are mild, the operation is simple and safe, the reaction yield is high, the production cost is low, three wastes are few, and greater implementation value and socioeconomic benefits are provided.

The invention is directed to modified guanine-containing nucleosides and nucleotides and uses thereof. More specifically, the invention relates to modified fluorescently labelled guanine-containing nucleosides and nucleotides which exhibit enhanced fluorophore intensity by virtue of reduced quenching effects.

The invention discloses a gel dressing based on G-quadruplex/collagen and a preparation method of the gel dressing. The preparation method comprises the following steps: adding guanine nucleoside, boric acid and potassium hydroxide to deionized water according to the proportion of the guanine nucleoside, to the boric acid to the potassium hydroxide being (1-3):1:1 and performing heating to 90-98 DEG C to obtain a G-quadruplex solution; cooling the G-quadruplex solution to 35-40 DEG C, adding collagen to disperse the solution till the concentration of the collagen in the solution is 2-10mg/mL, and performing cooling to room temperature so as to obtain the gel dressing based on G-quadruplex/collagen. The preparation method has the advantages of simple reaction conditions, few synthesis steps, short time and low production cost. When being used for wound healing, the gel dressing has good biocompatibility, good air permeability, strong adhesion properties, and high water content, and maintains humid environment, so that the wound is not liable to scab. The gel dressing disclosed by the invention does not contain any irritating ingredients, and is free from toxic and side effects. The gel dressing is used for accelerating wound healing and has a potential application value.

The invention belongs to the technical field of medicines, and particularly relates to new application of guanosine, in particular to new application of guanosine in preparation of medicines for treating asthma or inhibitors of MAPK, NF-kappa B and STAT3. The invention aims to solve the problem that safer and more effective asthma treatment medicines need to be developed urgently in the prior art.It is found that in an in-vitro THP-1-derived macrophage inflammation model, guanosine inhibits generation of a proinflammatory factor IL-6 by inhibiting activation of MAPK and NF-kappa B; in an asthma mouse model, guanosine reduces OVA-IgE of mouse plasma, reduces generation of IL-4, IL-6 and IL-13, relieves airway high reactivity, and relieves lung tissue cell infiltration, airway inflammationand collagen deposition. In addition, the expression levels of p-p38 MAPK, p-p65 NF-kappa B, p-I kappa B alpha and p-STAT3 proteins in lung tissues of mice in a guanosine treatment group are obviouslylower than those in an asthma model group. Therefore, the invention provides application of guanosine in preparation of a p38 MAPK inhibitor, a p65 NF-kappa B inhibitor, an STAT3 inhibitor or an asthma treatment drug.

The invention discloses an application of nucleoside hydrogel in preparation of a medicine for preventing or delaying canceration of oral mucosa potential malignant diseases. The nucleoside hydrogel is prepared by dissolving isoguanine nucleoside, guanine nucleoside and borate in water or an aqueous solution and then crosslinking. The experiments prove that the nucleoside hydrogel provided by theinvention can effectively inhibit proliferation of human oral mucosa precancerous lesion cells and delay canceration of oral leukoderma. Therefore, the nucleoside hydrogel provided by the invention has a good application prospect in preparation of drugs for preventing or delaying oral mucosa potential malignant diseases, especially oral leukoplakia canceration.

The invention relates to a preparation method of a novel modified nucleoside 2'-EOE-guanosine. In the method, 2,6-diamino-guanosine, as an initial raw material, is firstly reacted with a metal hydrideto generate a sodium alkoxide active intermediate, which is then reacted with 2-ethyl halide ethyl ether to generate a 2,6-diamino-guanosine intermediate, modified by a target group; finally througha biochemical reaction, an amino acid, on a specified locus of a compound B, is converted into a carbonyl group, thereby generating the target product, 2'-EOE-guanosine, at high yield and high selectivity. The method can easily and economically mass-synthesize the 2'-EOE-guanosine.

The invention discloses a method for preparing acyclovir, comprising synthesis of diacetylguanine, namely guanosine, acetic anhydride and boric acid are added to a reaction kettle at a weight ratio of1:6.4:0.006, the temperature is increased to 110-120 DEG C, and heat preservation is conducted for 6-12 hours; then the temperature is reduced to 60-100 DEG C, and heat preservation is conducted for6 hours, so the reaction is finished; subsequently, a part of the reaction liquid is distilled off under reduced pressure, the temperature is lowered to 3-5 DEG C to be maintained for 5 hours, discharging and centrifugal separation are conducted, rinsing with acetic anhydride is conducted for 3 times, and drying is conducted to obtain diacetylguanine. The method for preparing acyclovir provided bythe invention has the advantages that the process is easy to feed, the post-treatment is simple, the cost of the three-waste treatment is reduced, and ethanol is used as a recrystallization solvent,which not only reduces the cost, but also improves the product quality.

Inhibitory oligonucleotide having the general formula:

X₁ C C N₁ N₂ N₃ X₂ N₄ N₅ GGG N₆ X₃ N₇   (I)

are disclosed which can be used in pharmaceutical compositions, whereby in formula (I)

C is cytidine or a derivative thereof, whereby the cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide having a chemical modification involving the cytosine base, cytidine nucleoside sugar, or both the cytosine base and the cytidine nucleoside sugar, 2′-O-methylcytidine, 5-bromocytidine, 5-hydroxycytidine, ribocytidine and cytosine-β-D-arabinofuranoside,

G is guanosine or a derivative thereof, whereby the guanosine derivative is selected from the group consisting of 7-deazaguanosine, a guanosine-like nucleotide having a chemical modification involving the guanine base, the guanosine nucleoside sugar or both the guanine base and the guanosine nucleoside sugar,

X₁ and X₃ is any nucleotide sequence with 0 to 12 bases and each nucleotide is independent of any other, X₂ is any nucleotide sequence having 0 to 3 nucleotides,

N₁, N₂ and N₃are each independently any nucleotide,

N₄ and N₇ is a pyrimidine or a modified pyrimidine,

N₅ is a purin or a modified purin,

N₆ is a modified pyrimidine, A or a modified purin,

wherein at least two of the nucleotides N₄, N₅, N₆ or N₇ are modified purins or modified pyrimidines.

The invention provides a Sr<2+> responsive high polymer material, an ion imprinted gel and a gel grating. The high polymer material is formed by copolymerization of N-isopropylacrylamide and 5'-O-acryloyl-2', 3'-O-isopropylidene-guanosine, and the ion imprinted gel is formed by A G-tetramer unit, formed by copolymerization of 5'-O-acryloyl-2 ' 3'-O-isopropylidene-guanosine under induction of Sr<2+>, and Sr<2+>-containing gel formed by copolymerization crosslinking of N-isopropylacrylamide after Sr<2+> in a gel network is fully eluted, and the gel grating is composed of a substrate and parallel gel strips on the substrate. Each gel strip is composed of the ion imprinted gel. The invention also provides a trace Sr<2+> detection method. The environmental protection property of the Sr<2+> detection material can be improved, the detection difficulty of the Sr<2+> detection material is reduced, and sensitive and convenient detection of trace Sr<2+> is realized.